Companies around the world are confronting new risks of corporate misconduct in the rush to respond to the coronavirus outbreak, a global pandemic that has presented pitfalls as cost-cutting and other priorities threaten to undercut compliance programs.

In the scramble to address the global health crisis, governments and companies have been coordinating on the approval and distribution of potential treatments, medical equipment and other necessary products, leaving fertile ground for corruption in the space between the public and private sectors.